Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Pyxis Oncology Inc's Business Segments
Pyxis Oncology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Milestone Revenue
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Milestone Revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Milestone Revenue | $ 3 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Milestone Revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Milestone Revenue | $ 3 | - |
Description of Pyxis Oncology Inc
Pyxis Oncology Inc is a clinical-stage biopharmaceutical company which is focused on developing innovative cancer therapies. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.
Pyxis Oncology has a unique approach to cancer therapy, using a proprietary platform to identify and validate novel therapeutic targets. The platform is designed to identify targets that are important for tumor growth and survival, but are not currently targeted by existing therapies. This enables Pyxis to develop drugs that have the potential to be more effective and better tolerated than existing cancer treatments.
At the core of Pyxis Oncology's platform is a cutting-edge technology called Mass Spec. Mass Spec is a powerful tool that allows the company to identify thousands of proteins in tumor cells and compare them to normal cells. This enables Pyxis to identify proteins that are unique to cancer cells and target them with therapies that have a high specificity and low toxicity.
Pyxis Oncology's lead drug candidate is PYX-202, which is a monoclonal antibody targeting a protein called OX40. OX40 is a key regulator of T-cell function and has been shown to be important for tumor growth and survival. PYX-202 is currently in Phase I clinical trials for the treatment of advanced solid tumors.
In addition to PYX-202, Pyxis Oncology has a pipeline of other drug candidates targeting novel therapeutic targets. These include drugs targeting proteins such as CD73, CD39, and PSMA.
Pyxis Oncology has a world-class team of scientists and clinicians who have extensive experience in oncology drug development. The company has also built strong partnerships with leading academic institutions and pharmaceutical companies to accelerate the development of its drug candidates.
Overall, Pyxis Oncology is a promising biopharmaceutical company that is working to develop innovative cancer therapies that have the potential to make a significant impact on the lives of cancer patients.
Pyxis Oncology has a unique approach to cancer therapy, using a proprietary platform to identify and validate novel therapeutic targets. The platform is designed to identify targets that are important for tumor growth and survival, but are not currently targeted by existing therapies. This enables Pyxis to develop drugs that have the potential to be more effective and better tolerated than existing cancer treatments.
At the core of Pyxis Oncology's platform is a cutting-edge technology called Mass Spec. Mass Spec is a powerful tool that allows the company to identify thousands of proteins in tumor cells and compare them to normal cells. This enables Pyxis to identify proteins that are unique to cancer cells and target them with therapies that have a high specificity and low toxicity.
Pyxis Oncology's lead drug candidate is PYX-202, which is a monoclonal antibody targeting a protein called OX40. OX40 is a key regulator of T-cell function and has been shown to be important for tumor growth and survival. PYX-202 is currently in Phase I clinical trials for the treatment of advanced solid tumors.
In addition to PYX-202, Pyxis Oncology has a pipeline of other drug candidates targeting novel therapeutic targets. These include drugs targeting proteins such as CD73, CD39, and PSMA.
Pyxis Oncology has a world-class team of scientists and clinicians who have extensive experience in oncology drug development. The company has also built strong partnerships with leading academic institutions and pharmaceutical companies to accelerate the development of its drug candidates.
Overall, Pyxis Oncology is a promising biopharmaceutical company that is working to develop innovative cancer therapies that have the potential to make a significant impact on the lives of cancer patients.
Pyxis Oncology Inc is an innovative biotechnology company that focuses on the discovery and development of novel cancer therapies. With a commitment to enhancing treatment options for patients suffering from cancer, the company emphasizes its research and development (R&D) programs, which are anchored in areas such as immuno-oncology and targeted therapies. Below is an extensive description of the segments, products, and services offered by Pyxis Oncology Inc.
Segments:
1. Research and Development (R&D):
- Pyxis Oncology Inc has established a robust and innovative R&D pipeline aimed at discovering and developing new therapies tailored for the treatment of various cancers. The R&D division is multifaceted, involving extensive preclinical and clinical studies, and leveraging cutting-edge methodologies and technologies to identify potential therapeutic candidates.
- The company is committed to exploring the molecular underpinnings of cancer, targeting specific pathways that contribute to tumor growth and metastasis. This involves both early-stage assets, still in the research phase, as well as assets that have progressed to clinical trials, where their safety and efficacy are tested in human patients.
2. Manufacturing:
- The manufacturing segment of Pyxis Oncology Inc is equipped with state-of-the-art facilities designed to produce high-quality cancer therapies in compliance with regulatory standards. The company employs advanced technologies and practices throughout the manufacturing process, ensuring that products are developed with the utmost precision and safety.
- A dedicated team of experts oversees all aspects of drug manufacturing, which encompasses initial drug synthesis, formulation, scaling up processes, quality control, and the final packaging and distribution of therapies. This ensures a streamlined process from the lab to the clinic, allowing rapid and efficient delivery of new therapies to patients.
Products:
1. PYX-202:
- PYX-202 is a novel, first-in-class cancer therapy designed to target multiple biological pathways implicated in cancer development and progression. This targeted therapy has showcased significant efficacy in preclinical studies, demonstrating the ability to combat various types of cancers, particularly solid tumors.
- By focusing on specific molecular targets within cancer cells, PYX-202 aims to enhance treatment effectiveness while minimizing side effects associated with conventional cancer therapies. Continued studies aim to further elucidate its potential role in clinical settings.
2. PYX-203:
- PYX-203 is an innovative immuno-oncology therapy that works by stimulating the immune system to recognize and eradicate cancer cells. This therapy harnesses the body’s own immune mechanisms, enhancing natural immune responses against tumors.
- Preclinical findings have indicated promising results, positioning PYX-203 as a potential treatment option for a variety of cancers. The mechanism of action is designed to improve the visibility of cancer cells to the immune system, which may lead to more effective and durable responses.
Services:
1. Drug Discovery and Development Services:
- Pyxis Oncology Inc extends its expertise by offering drug discovery and development services to other pharmaceutical companies and research institutions. These services include providing access to specialized technology platforms, expert consultations, and research capabilities to accelerate the drug discovery process.
- By partnering with other organizations, Pyxis Oncology is dedicated to promoting collaborative efforts that can lead to the development of effective cancer treatments. The company’s team of scientists and researchers work closely with partners throughout the entire drug development lifecycle.
2. Clinical Trial Management Services:
- The company provides comprehensive clinical trial management services tailored for organizations conducting clinical trials for cancer therapies. This encompasses the design, implementation, and oversight of clinical studies.
- Pyxis Oncology Inc boasts a team of experienced professionals who manage critical phases of clinical trials, including patient recruitment, regulatory compliance, data collection and analysis, and reporting of results. Their goal is to facilitate efficient and effective clinical trials that yield reliable and valid outcomes.
Conclusion:
In summary, Pyxis Oncology Inc represents a forward-thinking entity in the biotechnology sector, focused on advancing the landscape of cancer treatment through innovative research and development, high-quality manufacturing, and specialized services. With a diverse portfolio that includes unique product offerings and collaborative services, Pyxis Oncology is poised to make significant contributions to the ongoing battle against cancer. The company’s dedication to harnessing the potential of immuno-oncology and targeted therapies underscores its commitment to improving patient outcomes and expanding treatment options in the field of oncology.
Segments:
1. Research and Development (R&D):
- Pyxis Oncology Inc has established a robust and innovative R&D pipeline aimed at discovering and developing new therapies tailored for the treatment of various cancers. The R&D division is multifaceted, involving extensive preclinical and clinical studies, and leveraging cutting-edge methodologies and technologies to identify potential therapeutic candidates.
- The company is committed to exploring the molecular underpinnings of cancer, targeting specific pathways that contribute to tumor growth and metastasis. This involves both early-stage assets, still in the research phase, as well as assets that have progressed to clinical trials, where their safety and efficacy are tested in human patients.
2. Manufacturing:
- The manufacturing segment of Pyxis Oncology Inc is equipped with state-of-the-art facilities designed to produce high-quality cancer therapies in compliance with regulatory standards. The company employs advanced technologies and practices throughout the manufacturing process, ensuring that products are developed with the utmost precision and safety.
- A dedicated team of experts oversees all aspects of drug manufacturing, which encompasses initial drug synthesis, formulation, scaling up processes, quality control, and the final packaging and distribution of therapies. This ensures a streamlined process from the lab to the clinic, allowing rapid and efficient delivery of new therapies to patients.
Products:
1. PYX-202:
- PYX-202 is a novel, first-in-class cancer therapy designed to target multiple biological pathways implicated in cancer development and progression. This targeted therapy has showcased significant efficacy in preclinical studies, demonstrating the ability to combat various types of cancers, particularly solid tumors.
- By focusing on specific molecular targets within cancer cells, PYX-202 aims to enhance treatment effectiveness while minimizing side effects associated with conventional cancer therapies. Continued studies aim to further elucidate its potential role in clinical settings.
2. PYX-203:
- PYX-203 is an innovative immuno-oncology therapy that works by stimulating the immune system to recognize and eradicate cancer cells. This therapy harnesses the body’s own immune mechanisms, enhancing natural immune responses against tumors.
- Preclinical findings have indicated promising results, positioning PYX-203 as a potential treatment option for a variety of cancers. The mechanism of action is designed to improve the visibility of cancer cells to the immune system, which may lead to more effective and durable responses.
Services:
1. Drug Discovery and Development Services:
- Pyxis Oncology Inc extends its expertise by offering drug discovery and development services to other pharmaceutical companies and research institutions. These services include providing access to specialized technology platforms, expert consultations, and research capabilities to accelerate the drug discovery process.
- By partnering with other organizations, Pyxis Oncology is dedicated to promoting collaborative efforts that can lead to the development of effective cancer treatments. The company’s team of scientists and researchers work closely with partners throughout the entire drug development lifecycle.
2. Clinical Trial Management Services:
- The company provides comprehensive clinical trial management services tailored for organizations conducting clinical trials for cancer therapies. This encompasses the design, implementation, and oversight of clinical studies.
- Pyxis Oncology Inc boasts a team of experienced professionals who manage critical phases of clinical trials, including patient recruitment, regulatory compliance, data collection and analysis, and reporting of results. Their goal is to facilitate efficient and effective clinical trials that yield reliable and valid outcomes.
Conclusion:
In summary, Pyxis Oncology Inc represents a forward-thinking entity in the biotechnology sector, focused on advancing the landscape of cancer treatment through innovative research and development, high-quality manufacturing, and specialized services. With a diverse portfolio that includes unique product offerings and collaborative services, Pyxis Oncology is poised to make significant contributions to the ongoing battle against cancer. The company’s dedication to harnessing the potential of immuno-oncology and targeted therapies underscores its commitment to improving patient outcomes and expanding treatment options in the field of oncology.